Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
RTK protein kinase inhibitor ABT 869, 5 mg  

RTK protein kinase inhibitor ABT 869, 5 mg

1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea

ABT 869 is a multi-targeted receptor tyrosine kinase (RTK) inhibitor, targeting VEGRFs, PDGFRs, Fms-like tyrosine kinase-3 and c-KIT.
Synonyms: Linifanib

More details

PKI-ABT869-005

Availability: within 3 days

130,00 €

Background: ABT 869 is a multi-targeted receptor tyrosine kinase (RTK) inhibitor, targeting VEGFRs, PDGFRs, Fms-like tyrosine kinase-3 and c-KIT. In cellular assays ABT869 inhibits RTK phosphorylation (IC50 = 2, 4, and 7 nM for PDGFR-β, KDR, and CSF-1R, respectively) and VEGF-stimulated proliferation (IC50 = 0.2 nM for human endothelial cells).

Chemical formula: C21H18FN5O
Molecular weight: 375.40 g/mol
Purity: 99 %
Appearance: Grey solid
Solubility: Soluble in DMSO
CAS Number: 796967-16-3

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

DH Albert et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 2006, 5, 995-1006.
 
J Zhou et al. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J. Hematol. Oncol. 2009, 2, 33.
 
AK Ikeda et al. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol. Cancer Ther. 2010, 9(3), 653-60.

The following products could also be interesting for you: